Haematological aspects of HIV infection.
Multiple interacting factors contribute to the haematological manifestations of HIV disease. The effects of HIV-1 infection influence all haemopoietic cell lineages resulting in a spectrum of haematological abnormalities. Even in the absence of other pathological processes, bone marrow morphology is invariably abnormal, and anaemia, neutropenia and thrombocytopenia are all common during the course of disease. Intercurrent opportunistic infections may cause bone marrow suppression or induce specific cytopenias. Therapies used to treat HIV and its complications are frequently implicated as the cause of haematological dysfunction, and many have significant myelotoxic side-effects. Insights into the molecular basis for many of these abnormalities have permitted a clearer understanding of the pathophysiology of HIV-1 infection. Recombinant human growth factors that may be used to treat isolated cytopenias or to ameliorate the myelotoxic effects of other essential therapies. Lymph opoietic growth factors and the use of gene modified cells provide future therapeutic strategies that may alter the course of HIV disease.
Evans
R H
RH
AIDS Research Center & Massachusetts General Hospital Cancer Center, Harvard Medical School, 149 13th Street, Room 5212, Boston, Massachusetts 02129, USA.
Scadden
D T
DT
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000150:complications*; D000740:Anemia / Q000473:pathology / Q000821:virology; D015497:HIV-1; D006402:Hematologic Diseases / Q000473:pathology / Q000821:virology*; D006801:Humans; D009503:Neutropenia / Q000473:pathology / Q000821:virology; D013921:Thrombocytopenia / Q000473:pathology / Q000821:virology